Read more
This SpringerBrief gives the latest research on the role of miRNAs in breast cancer metastasis. MicroRNAs (miRNAs) are recently described small endogenous noncoding RNAs implicated in the posttranscriptional control of gene expression. These tiny molecules are involved in developmental, physiologic phenomenon as well as pathologic processes including cancers. In fact, miRNAs have emerged as critical regulators of cancer progression, invasion and metastasis. This is mainly because a single miRNA can affect several downstream genes and signaling pathways with oncogenic or tumor suppressor actions depending on the target genes affected. Due to this multimodal downstream signaling effects, these small endogenous molecules hold great promise in metastasis prevention and treatment. Modulating the activity of miRNAs can provide opportunities for novel cancer interventions. Targeting miRNAs could become a novel prognostic and therapeutic strategy to prevent the future development of metastasis. Thus, miRNAs could also serve as a potential targets for anti-metastatic therapy. The book explores how the expression of miRNAs in the primary tumor could be silenced using antagomirs (chemically modified anti-miRNA oligonucleotides), which could prevent the development of metastasis; whereas once metastasis develops then it could be treated with miRNA mimics for inducing its expression for the treatment. Therefore, development of miRNA-based prophylactic therapies could serve as precision and personalized medicine against future development of metastasis of breast and other cancers.
List of contents
Role of miRNAs and their Target Genes in Breast Cancer Metastasis.- Molecular Pathogenesis of Breast Cancer and the Role of MicroRNAs.- Epidemiology, Risk Factors, Treatment and Prevention of Breast Cancer Metastases.- Clinical Perspectives: Breast Cancer Brain Metastasis.- Molecular targeted therapy for brain metastatic breast cancers: Current Updates
About the author
Seema Sethi, MD, is a Research Assistant Professor in the Department of Pathology at Wayne State University. Dr Sethi’s research interests are in developing non-invasive molecular cytogenetic approaches for early diagnosis, prognosis and therapeutics of cancer, mainly breast, cervix and head and neck cancer. Currently, she is involved in several ongoing projects evaluating the role of biomarkers in the pathogenetic evolution of malignancies. Dr. Sethi has published 5 book chapters and 62 scientific papers and has received over 490 citations. She is the recipient of several poster and research awards.
Summary
This SpringerBrief gives the latest research on the role of miRNAs in breast cancer metastasis. MicroRNAs (miRNAs) are recently described small endogenous noncoding RNAs implicated in the posttranscriptional control of gene expression. These tiny molecules are involved in developmental, physiologic phenomenon as well as pathologic processes including cancers. In fact, miRNAs have emerged as critical regulators of cancer progression, invasion and metastasis. This is mainly because a single miRNA can affect several downstream genes and signaling pathways with oncogenic or tumor suppressor actions depending on the target genes affected. Due to this multimodal downstream signaling effects, these small endogenous molecules hold great promise in metastasis prevention and treatment. Modulating the activity of miRNAs can provide opportunities for novel cancer interventions. Targeting miRNAs could become a novel prognostic and therapeutic strategy to prevent the future development of metastasis. Thus, miRNAs could also serve as a potential targets for anti-metastatic therapy. The book explores how the expression of miRNAs in the primary tumor could be silenced using antagomirs (chemically modified anti-miRNA oligonucleotides), which could prevent the development of metastasis; whereas once metastasis develops then it could be treated with miRNA mimics for inducing its expression for the treatment. Therefore, development of miRNA-based prophylactic therapies could serve as precision and personalized medicine against future development of metastasis of breast and other cancers.
